Monoclonal Antibodies & Antibody-Drug Conjugates: From Lab To Life-Changing Therapies

Antibody‑based therapeutics continue to advance rapidly, but developing monoclonal antibodies and antibody‑drug conjugates demands precise analytical control at every stage. This flyer highlights a comprehensive suite of solutions designed to support developers from early research through commercial release. It covers the full spectrum of characterization needs, including primary and higher‑order structure analysis, purity and heterogeneity profiling, potency evaluation, and in‑depth genetic QC of CHO cell lines. The testing portfolio spans essential methods such as HDX, CE‑SDS, cIEF, SEC‑MALS, cell‑based bioassays, ELISA, SPR, and advanced LC‑MS approaches for conjugation confirmation and DAR assessment.

Beyond characterization, the flyer outlines robust method development and validation services built around orthogonal strategies that reduce risk and strengthen regulatory confidence. Developers also gain access to broad stability capabilities—from accelerated to long‑term studies — and a full biosafety and microbiology package to safeguard product integrity. Whether supporting early‑phase comparability or commercial‑stage release testing, this resource provides a clear view of the analytical depth required to ensure quality, safety, and functional performance. Download the full flyer to explore how each testing category aligns with the complexities of modern mAbs and ADCs.